4WO Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.45 |
| 52 Week High | HK$0.52 |
| 52 Week Low | HK$0.33 |
| Beta | 0.51 |
| 11 Month Change | -7.00% |
| 3 Month Change | n/a |
| 1 Year Change | -49.50% |
| 33 Year Change | -76.58% |
| 5 Year Change | n/a |
| Change since IPO | -84.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4WO | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -1.0% | -0.02% |
| 1Y | -49.5% | -7.3% | 8.2% |
Return vs Industry: 4WO underperformed the German Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: 4WO underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 4WO volatility | |
|---|---|
| 4WO Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 4WO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4WO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,050 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; Sutra Hemi Valve, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ which is transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral balloon catheter; TaurusExplora, a pre-shaped guidewire; and TaurusNavi, an introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Fastunnel, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
| 4WO fundamental statistics | |
|---|---|
| Market cap | €313.10m |
| Earnings (TTM) | -€33.36m |
| Revenue (TTM) | €68.58m |
4.6x
P/S Ratio-9.4x
P/E RatioIs 4WO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4WO income statement (TTM) | |
|---|---|
| Revenue | CN¥517.46m |
| Cost of Revenue | CN¥146.18m |
| Gross Profit | CN¥371.28m |
| Other Expenses | CN¥623.02m |
| Earnings | -CN¥251.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 71.75% |
| Net Profit Margin | -48.65% |
| Debt/Equity Ratio | 11.4% |
How did 4WO perform over the long term?
See historical performance and comparison